cilostazol has been researched along with Reperfusion Injury in 33 studies
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia-reperfusion injury, in PAD patients." | 9.14 | The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. ( Badger, SA; Lee, B; Makar, RR; McEneny, J; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009) |
| "This study aims to determine the protective effect of cilostazol on myocardium in obese Wistar rats with induced ischemia-reperfusion injury (IRI)." | 8.31 | Effects of Cilostazol on the Myocardium in an Obese Wistar Rat Model of Ischemia-Reperfusion Injury. ( Demir, T; Ilal Mert, FT; Sahin, M; Sarac, F, 2023) |
| "To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models." | 8.12 | Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022) |
| "The aim of this study was to evaluate the pretreatment effect of cilostazol on spinal cord ischemia-reperfusion injury." | 7.81 | Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. ( Alpay, MF; Cakir, O; Colak, N; Erdamar, H; Haltas, H; Namuslu, M; Nazli, Y; Nuri Aksoy, O; Olgun Akkaya, I, 2015) |
| " Cilostazol pre-treatment protected against cold hepatic ischemia-reperfusion injury by preventing hepatocellular disintegration, ICAM-1-associated endothelial inflammation, and apoptotic death." | 7.81 | Preconditioning by cilostazol protects against cold hepatic ischemia-reperfusion injury. ( Keppler, U; Menger, MD; Moussavian, MR; Müller, S; Scheuer, C; Schilling, MK; Strowitzki, MJ; von Heesen, M, 2015) |
| "To evaluate effects of ischemic preconditioning and Cilostazol on muscle ischemia-reperfusion injury." | 7.80 | Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. ( Frias Neto, CA; Koike, MK; Montero, EF; Saad, KR; Saad, PF, 2014) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 7.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment." | 7.78 | The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012) |
| "Cilostazol had no protective effect on the kidney and the skeletal striated muscle in rats submitted to acute ischemia and reperfusion in this model." | 7.78 | Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012) |
| " The present study examined whether or not cilostazol reduces the myocardial infarct size, and investigated its mechanism in a rabbit model of myocardial infarction." | 7.77 | Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. ( Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y, 2011) |
| "Treatment with cilostazol significantly improved pathological findings associated with liver I/R injury and increased survival rate compared to that in controls." | 5.46 | Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury. ( Abe, Y; Fujii, T; Fujimura, N; Hibi, T; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Matsubara, K; Obara, H; Sakamoto, M; Shinoda, M; Tanabe, M; Yagi, H, 2017) |
| "Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage." | 5.36 | The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. ( Hattori, K; Kajimura, M; Morikawa, T; Suematsu, M, 2010) |
| "Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia-reperfusion injury, in PAD patients." | 5.14 | The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. ( Badger, SA; Lee, B; Makar, RR; McEneny, J; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009) |
| "This study aims to determine the protective effect of cilostazol on myocardium in obese Wistar rats with induced ischemia-reperfusion injury (IRI)." | 4.31 | Effects of Cilostazol on the Myocardium in an Obese Wistar Rat Model of Ischemia-Reperfusion Injury. ( Demir, T; Ilal Mert, FT; Sahin, M; Sarac, F, 2023) |
| "To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models." | 4.12 | Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022) |
| "The aim of this study was to evaluate the pretreatment effect of cilostazol on spinal cord ischemia-reperfusion injury." | 3.81 | Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. ( Alpay, MF; Cakir, O; Colak, N; Erdamar, H; Haltas, H; Namuslu, M; Nazli, Y; Nuri Aksoy, O; Olgun Akkaya, I, 2015) |
| " Cilostazol pre-treatment protected against cold hepatic ischemia-reperfusion injury by preventing hepatocellular disintegration, ICAM-1-associated endothelial inflammation, and apoptotic death." | 3.81 | Preconditioning by cilostazol protects against cold hepatic ischemia-reperfusion injury. ( Keppler, U; Menger, MD; Moussavian, MR; Müller, S; Scheuer, C; Schilling, MK; Strowitzki, MJ; von Heesen, M, 2015) |
| "We investigated the effects of cilostazol, a selective inhibitor of phosphodiesterase 3, on blood-brain barrier (BBB) integrity against ischemia-reperfusion injury enhanced by advanced glycation endproducts (AGEs)." | 3.80 | Cilostazol attenuates ischemia-reperfusion-induced blood-brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-β1 signaling. ( Deli, MA; Hayashi, K; Nagata, I; Nakagawa, S; Niwa, M; So, G; Takeshita, T; Tanaka, K; Tatsumi, R, 2014) |
| "To evaluate effects of ischemic preconditioning and Cilostazol on muscle ischemia-reperfusion injury." | 3.80 | Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. ( Frias Neto, CA; Koike, MK; Montero, EF; Saad, KR; Saad, PF, 2014) |
| "Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice." | 3.78 | Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012) |
| "Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment." | 3.78 | The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012) |
| "Cilostazol had no protective effect on the kidney and the skeletal striated muscle in rats submitted to acute ischemia and reperfusion in this model." | 3.78 | Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012) |
| " The present study examined whether or not cilostazol reduces the myocardial infarct size, and investigated its mechanism in a rabbit model of myocardial infarction." | 3.77 | Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. ( Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y, 2011) |
| "Cilostazol (CLZ) is a selective phosphodiesterase (PDE) 3A inhibitor used for treatment of intermittent claudication." | 1.62 | Dose dependent effect of cilostazol in induced testicular ischemia reperfusion via modulation of HIF/VEGF and cAMP/SIRT1 pathways. ( Ahmed Ibrahim, R; Refaie, MMM; Shehata, S, 2021) |
| "Treatment with cilostazol significantly improved pathological findings associated with liver I/R injury and increased survival rate compared to that in controls." | 1.46 | Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury. ( Abe, Y; Fujii, T; Fujimura, N; Hibi, T; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Matsubara, K; Obara, H; Sakamoto, M; Shinoda, M; Tanabe, M; Yagi, H, 2017) |
| "Cilostazol(CTL) is a phosphodiesterase inhibitor, which has been widely used as anti-platelet agent." | 1.43 | Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1. ( Li, M; Liu, F; Liu, P; Ma, JY; Mei, XY; Miu, JC; Qi, DS; Qu, R; Tao, JH; Wang, M; Zhang, F; Zhang, LQ; Zhang, SC, 2016) |
| "Cilostazol is a phosphodiesterase inhibitor that has anti-inflammatory potential in addition to vasodilator and antiplatelet effects." | 1.40 | Effects of cilostazol on oxidative stress, systemic cytokine release, and spinal cord injury in a rat model of transient aortic occlusion. ( Basoglu, H; Cetin, NK; Discigil, B; Kurtoglu, T; Ozkisacik, EA; Tataroglu, C; Yenisey, C, 2014) |
| "Pretreatment with cilostazol or pioglitazone provided significant protection against the I/R-induced renal injury as manifested by the attenuated serum levels of creatinine, blood urea nitrogen and cystatin C." | 1.40 | Cilostazol renoprotective effect: modulation of PPAR-γ, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion. ( Abdallah, DM; El-Abhar, HS; Ragab, D, 2014) |
| "Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage." | 1.36 | The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. ( Hattori, K; Kajimura, M; Morikawa, T; Suematsu, M, 2010) |
| "Cilostazol inhibits the increase in compartment pressure central to the development of the compartment syndrome." | 1.30 | Selective type III phosphodiesterase inhibition prevents elevated compartment pressure after ischemia/reperfusion injury. ( Cunningham, L; Hakaim, AG; Hoover, K; White, JL, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 6 (18.18) | 29.6817 |
| 2010's | 20 (60.61) | 24.3611 |
| 2020's | 6 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Refaie, MMM | 2 |
| Ahmed Ibrahim, R | 1 |
| Shehata, S | 2 |
| Sahin, M | 2 |
| Baytaroglu, C | 1 |
| Sevgili, E | 1 |
| El-Hussieny, M | 1 |
| Demir, T | 1 |
| Ilal Mert, FT | 1 |
| Sarac, F | 1 |
| Gülaştı, ÖF | 1 |
| Yavuz, Ş | 1 |
| Arıkan, AA | 1 |
| Eraldemir, FC | 1 |
| Özbudak, E | 1 |
| Şahin, D | 1 |
| Kır, HM | 1 |
| Gendy, AM | 1 |
| Amin, MM | 1 |
| Al-Mokaddem, AK | 1 |
| Abd Ellah, MF | 1 |
| Inan, B | 1 |
| Sönmez Ergün, S | 1 |
| Nurten, A | 1 |
| Küçükgergin, C | 1 |
| Zengin Türkmen, A | 1 |
| Seçkin, Ş | 1 |
| Erkalp, K | 1 |
| Ziyade, S | 1 |
| Fujii, T | 1 |
| Obara, H | 1 |
| Matsubara, K | 1 |
| Fujimura, N | 1 |
| Yagi, H | 1 |
| Hibi, T | 1 |
| Abe, Y | 1 |
| Kitago, M | 1 |
| Shinoda, M | 1 |
| Itano, O | 1 |
| Tanabe, M | 1 |
| Masugi, Y | 1 |
| Sakamoto, M | 1 |
| Kitagawa, Y | 1 |
| Nan, D | 1 |
| Jin, H | 1 |
| Deng, J | 1 |
| Yu, W | 1 |
| Liu, R | 1 |
| Sun, W | 1 |
| Huang, Y | 1 |
| Souza Júnior, SS | 2 |
| Moreira Neto, AA | 2 |
| Schmidt Júnior, AF | 2 |
| Lemos, JB | 1 |
| Rodrigues, OR | 2 |
| Takeshita, T | 1 |
| Nakagawa, S | 1 |
| Tatsumi, R | 1 |
| So, G | 1 |
| Hayashi, K | 1 |
| Tanaka, K | 1 |
| Deli, MA | 1 |
| Nagata, I | 1 |
| Niwa, M | 1 |
| Kurtoglu, T | 1 |
| Basoglu, H | 1 |
| Ozkisacik, EA | 1 |
| Cetin, NK | 1 |
| Tataroglu, C | 1 |
| Yenisey, C | 1 |
| Discigil, B | 1 |
| Ragab, D | 1 |
| Abdallah, DM | 1 |
| El-Abhar, HS | 1 |
| Frias Neto, CA | 1 |
| Koike, MK | 1 |
| Saad, KR | 1 |
| Saad, PF | 1 |
| Montero, EF | 1 |
| Nazli, Y | 1 |
| Colak, N | 1 |
| Namuslu, M | 1 |
| Erdamar, H | 1 |
| Haltas, H | 1 |
| Alpay, MF | 1 |
| Nuri Aksoy, O | 1 |
| Olgun Akkaya, I | 1 |
| Cakir, O | 1 |
| von Heesen, M | 1 |
| Müller, S | 1 |
| Keppler, U | 1 |
| Strowitzki, MJ | 1 |
| Scheuer, C | 1 |
| Schilling, MK | 1 |
| Menger, MD | 1 |
| Moussavian, MR | 1 |
| Joe, Y | 1 |
| Zheng, M | 1 |
| Kim, HJ | 1 |
| Uddin, MJ | 1 |
| Kim, SK | 1 |
| Chen, Y | 1 |
| Park, J | 1 |
| Cho, GJ | 1 |
| Ryter, SW | 1 |
| Chung, HT | 1 |
| Nagai, N | 1 |
| Yoshioka, C | 1 |
| Ito, Y | 2 |
| Funakami, Y | 1 |
| Nishikawa, H | 1 |
| Kawabata, A | 1 |
| Qi, DS | 1 |
| Tao, JH | 1 |
| Zhang, LQ | 1 |
| Li, M | 1 |
| Wang, M | 1 |
| Qu, R | 1 |
| Zhang, SC | 1 |
| Liu, P | 1 |
| Liu, F | 1 |
| Miu, JC | 1 |
| Ma, JY | 1 |
| Mei, XY | 1 |
| Zhang, F | 1 |
| O'Donnell, ME | 1 |
| Badger, SA | 1 |
| Sharif, MA | 1 |
| Makar, RR | 1 |
| McEneny, J | 1 |
| Young, IS | 1 |
| Lee, B | 1 |
| Soong, CV | 1 |
| Morikawa, T | 1 |
| Hattori, K | 1 |
| Kajimura, M | 1 |
| Suematsu, M | 1 |
| Sahin, MA | 1 |
| Onan, B | 1 |
| Guler, A | 1 |
| Oztas, E | 1 |
| Uysal, B | 1 |
| Arslan, S | 1 |
| Demirkilic, U | 1 |
| Tatar, H | 1 |
| Bai, Y | 1 |
| Murakami, H | 1 |
| Iwasa, M | 1 |
| Sumi, S | 1 |
| Yamada, Y | 1 |
| Ushikoshi, H | 1 |
| Aoyama, T | 1 |
| Nishigaki, K | 1 |
| Takemura, G | 1 |
| Uno, B | 1 |
| Minatoguchi, S | 1 |
| Reis, F | 1 |
| Kasahara, Y | 1 |
| Nakagomi, T | 1 |
| Matsuyama, T | 1 |
| Stern, D | 1 |
| Taguchi, A | 1 |
| Santos, MR | 1 |
| Celotto, AC | 1 |
| Capellini, VK | 1 |
| Evora, PR | 1 |
| Piccinato, CE | 1 |
| Joviliano, EE | 1 |
| Capelozzi, VL | 1 |
| Parra-Cuentas, ER | 1 |
| Francisco Neto, A | 1 |
| Lee, JH | 2 |
| Kim, KY | 2 |
| Lee, YK | 1 |
| Park, SY | 1 |
| Kim, CD | 1 |
| Lee, WS | 1 |
| Rhim, BY | 1 |
| Hong, KW | 2 |
| Iba, T | 2 |
| Kidokoro, A | 1 |
| Fukunaga, M | 1 |
| Takuhiro, K | 1 |
| Ouchi, M | 1 |
| Manickavasagam, S | 1 |
| Ye, Y | 1 |
| Lin, Y | 1 |
| Perez-Polo, RJ | 1 |
| Huang, MH | 1 |
| Lui, CY | 1 |
| Hughes, MG | 1 |
| McAdoo, DJ | 1 |
| Uretsky, BF | 1 |
| Birnbaum, Y | 1 |
| Hakaim, AG | 1 |
| Cunningham, L | 1 |
| White, JL | 1 |
| Hoover, K | 1 |
| Choi, JM | 1 |
| Shin, HK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients[NCT05671497] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for cilostazol and Reperfusion Injury
| Article | Year |
|---|---|
[Pretreatment with cilostazol protects against the vascular endothelial damage after ischemia/reperfusion].
Topics: Animals; Aspirin; Cilostazol; Dipyridamole; Endothelial Cells; Ischemic Preconditioning; Mice; Phosp | 2008 |
1 trial available for cilostazol and Reperfusion Injury
| Article | Year |
|---|---|
The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; alpha-Tocopherol; Ascorbate Oxidase; beta Carotene; C-R | 2009 |
31 other studies available for cilostazol and Reperfusion Injury
| Article | Year |
|---|---|
Dose dependent effect of cilostazol in induced testicular ischemia reperfusion via modulation of HIF/VEGF and cAMP/SIRT1 pathways.
Topics: Animals; Blotting, Western; Cilostazol; Cyclic AMP; Dose-Response Relationship, Drug; Interleukin-1b | 2021 |
Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model.
Topics: Adenosine Triphosphate; Animals; Cilostazol; Disease Models, Animal; Ischemia; Rats; Rats, Wistar; R | 2022 |
TLR4/NF-κB/TNFα and cAMP/SIRT1 signaling cascade involved in mediating the dose-dependent effect of cilostazol in ovarian ischemia reperfusion-induced injury.
Topics: Animals; Antioxidants; Cilostazol; NF-kappa B; Rats; Reperfusion; Reperfusion Injury; Sirtuin 1; Tol | 2022 |
Effects of Cilostazol on the Myocardium in an Obese Wistar Rat Model of Ischemia-Reperfusion Injury.
Topics: Animals; Cilostazol; Myocardium; Plasminogen Activator Inhibitor 1; Rats; Rats, Wistar; Reperfusion | 2023 |
Comparison of Cilostazol and Naftidrofuryl in an Experimental Acute Ischemia-Reperfusion Model.
Topics: Animals; Antioxidants; Biomarkers; Brain; Cilostazol; Disease Models, Animal; Kidney; Liver; Male; M | 2021 |
Cilostazol mitigates mesenteric ischemia/reperfusion-induced lung lesion: Contribution of PPAR-γ, NF-κB, and STAT3 crosstalk.
Topics: Animals; Bronchodilator Agents; Cilostazol; Gene Expression Regulation; Lung Diseases; Male; Mesente | 2021 |
Effects of Cilostazol and Diltiazem Hydrochloride on Ischemia-Reperfusion Injury in a Rat Hindlimb Model.
Topics: Animals; Calcium Channel Blockers; Cilostazol; Diltiazem; Disease Models, Animal; Drug Therapy, Comb | 2017 |
Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury.
Topics: Administration, Oral; Animals; Biomarkers; Cilostazol; Drug Administration Schedule; Liver; Male; Ph | 2017 |
Cilostazol ameliorates ischemia/reperfusion-induced tight junction disruption in brain endothelial cells by inhibiting endoplasmic reticulum stress.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cilostazol; Cyclic AMP; Drug Evaluation, Preclinical; | 2019 |
Biochemical study of the effects of cilostazol in rats subjected to acute ischemia and reperfusion of hind limbs.
Topics: Animals; Cilostazol; Creatinine; Disease Models, Animal; Hindlimb; Male; Myoglobin; Platelet Aggrega | 2013 |
Cilostazol attenuates ischemia-reperfusion-induced blood-brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-β1 signaling.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Capillary Permeability; Cell Hypoxia; Cells, Cultured; Cil | 2014 |
Effects of cilostazol on oxidative stress, systemic cytokine release, and spinal cord injury in a rat model of transient aortic occlusion.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Abdominal; Biomarkers; Cell Survival; Cilost | 2014 |
Cilostazol renoprotective effect: modulation of PPAR-γ, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Blood Urea Nitrogen; Caspase 1; Cell Adhesion Mo | 2014 |
Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats.
Topics: Animals; Cilostazol; Hindlimb; Ischemia; Ischemic Preconditioning; Male; Models, Animal; Muscle Fibe | 2014 |
Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits.
Topics: Animals; Cilostazol; Disease Models, Animal; Phosphodiesterase 3 Inhibitors; Prospective Studies; Ra | 2015 |
Preconditioning by cilostazol protects against cold hepatic ischemia-reperfusion injury.
Topics: Animals; Apoptosis; Cilostazol; Endothelial Cells; Female; Intercellular Adhesion Molecule-1; Ischem | 2015 |
Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis.
Topics: Animals; Cilostazol; Cytoprotection; Disease Models, Animal; DNA-Binding Proteins; Gene Expression R | 2015 |
Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model.
Topics: Administration, Intravenous; Animals; Blood Pressure; Brain; Cilostazol; Infarction, Middle Cerebral | 2015 |
Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1.
Topics: Animals; Apoptosis; Brain Ischemia; Caspase 3; Cilostazol; Cognition Disorders; Disease Models, Anim | 2016 |
The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum.
Topics: Animals; Brain Ischemia; Cerebrum; Cilostazol; Male; Mice; Mice, Inbred C57BL; Organ Specificity; Ox | 2010 |
Cilostazol, a type III phosphodiesterase inhibitor, reduces ischemia/reperfusion-induced spinal cord injury.
Topics: Animals; Cilostazol; Male; Phosphodiesterase 3 Inhibitors; Rats; Rats, Wistar; Reperfusion Injury; S | 2011 |
Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels.
Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Decanoic Acids; Disease Models, Animal; Drug Eva | 2011 |
Are threshold levels of signal transduction required for the protective effect of cilostazol against cardiac ischaemia-reperfusion injury?
Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Humans; Myocardial Infarction; Nitric Oxide; Pot | 2011 |
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry; | 2012 |
The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway.
Topics: Animals; Cilostazol; Disease Models, Animal; Femoral Artery; Hindlimb; Ischemia; Male; Nitric Oxide; | 2012 |
Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs.
Topics: Animals; Apoptosis; Caspase 3; Cilostazol; Disease Models, Animal; Hindlimb; In Situ Nick-End Labeli | 2012 |
Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats.
Topics: Animals; Blood-Brain Barrier; Blotting, Western; Brain Ischemia; Casein Kinase II; Chromosomes; Cilo | 2004 |
Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aspirin; Cilostazol; Cyclic Nucleotide Phosphodiestera | 2006 |
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
Topics: Adenosine; Administration, Oral; Animals; Atorvastatin; Body Weight; Cilostazol; Cyclic AMP-Dependen | 2007 |
Selective type III phosphodiesterase inhibition prevents elevated compartment pressure after ischemia/reperfusion injury.
Topics: Animals; Anterior Compartment Syndrome; Cilostazol; Hindlimb; Muscle, Skeletal; Oxygen Consumption; | 1999 |
Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain Infarction; Cilostazol; Cyc | 2002 |